Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK 4027 is a PCAF/GCN5 bromodomain chemical probe. In a time-resolved fluorescence resonance energy transfer (TR-FRET) assay, it has a pIC50 of 7.4±0.11 for PCAF.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 681 | 5日内发货 | ||
5 mg | ¥ 1,130 | 5日内发货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,180 | 5日内发货 |
产品描述 | GSK 4027 is a PCAF/GCN5 bromodomain chemical probe. In a time-resolved fluorescence resonance energy transfer (TR-FRET) assay, it has a pIC50 of 7.4±0.11 for PCAF. |
靶点活性 | PCAF:(pic50)7.4±0.11 |
体外活性 | The selectivity of GSK 4027 against the wider bromodomain family is assessed in the BROMOscan panel (pKi of 8.9 and 8.9 for PCAF and GCN5, respectively). GSK 4027 displays equipotent activity against PCAF and GCN5 (Ki: 1.4 nM for both bromodomains). GSK 4027 also demonstrates potency toward BRD4 BD1 and BRD9 inTR-FRET assay with pIC50s of <4.3 and 5.1±0.08, respectively. Due to the encouraging measured artificial membrane permeability (500 nm/s), treatment of HEK293 cells with GSK 4027 displace full-length PCAF from histone H3.3 with little drop-off from the biochemical assay and a pIC50 7.2 (IC50 60 nM)[1]. |
分子量 | 377.28 |
分子式 | C17H21BrN4O |
CAS No. | 2079896-25-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (132.53 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.6506 mL | 13.2528 mL | 26.5055 mL | 66.2638 mL |
5 mM | 0.5301 mL | 2.6506 mL | 5.3011 mL | 13.2528 mL | |
10 mM | 0.2651 mL | 1.3253 mL | 2.6506 mL | 6.6264 mL | |
20 mM | 0.1325 mL | 0.6626 mL | 1.3253 mL | 3.3132 mL | |
50 mM | 0.053 mL | 0.2651 mL | 0.5301 mL | 1.3253 mL | |
100 mM | 0.0265 mL | 0.1325 mL | 0.2651 mL | 0.6626 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GSK 4027 2079896-25-4 Others GSK4027 GSK-4027 Inhibitor inhibitor inhibit